Back

Real-world impact of intermittent levosimendan on survival, hospitalizations, and healthcare costs in advanced heart failure

31 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Trends and challenges in heart failure management Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Joao Fernandes Pedro

Santa Maria Hospital - CHULN, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail
Prediction model of rehospitalization in heart failure with preserved and mildly-reduced ejection fraction: the AD2NER risk score
Doctor F. Stoiculescu (Craiova, RO)
Abstract Slides Video
Presentation thumbnail
Prevalence, prognosis, and factors associated with heart failure with improved ejection fraction: single centre experience
Doctor M. Vidak (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of cardio-renal-anemia syndrome in heart failure - a report from the JROADHF database.
Doctor E. Noda (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and mapping of post-discharge care: insights from a slovakian cohort study
Mr M. Selvek (Bratislava, SK)
Abstract Slides Video
Presentation thumbnail
Delay in assistance effects in cardiology consultation following primary care physician referral in heart failure patients
Professor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Trends and challenges in heart failure management

The Event

Event poster

ESC Congress 2025

31 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study
19 May 2025
thumbnail
Congress Presentation
A value-based analysis of the systematic use of dapagliflozin in patients with heart failure
29 August 2025
thumbnail
Congress Presentation
Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre
11 May 2026
thumbnail
Congress Session
Evolving strategies in heart failure management
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources